公开(公告)号：US20250041323A1

公开(公告)日：2025-02-06

申请号：US18842959

申请日：2023-03-01

Applicant: YAMASA CORPORATION

Inventor： Kosuke NAKAGAWARA ,  Kazuya ISHIGE

IPC: A61K31/7072

Abstract: A BDNF production promoter includes at least one pyrimidine nucleotide or a precursor thereof as an active ingredient.

公开(公告)号：US20250019703A1

公开(公告)日：2025-01-16

申请号：US18711961

申请日：2022-07-15

Applicant: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Inventor： Dongjun LEE ,  Jayoung KIM

IPC: C12N15/113 ,  A61K31/337 ,  A61K31/7072 ,  A61P35/02

Abstract: One aspect relates to a pharmaceutical composition for the prevention or treatment of blood cancer, comprising a surfeit locus protein 4 (SURF4) inhibitor. The composition according to one aspect inhibits SURF4 to increase the expression of pJNK and decrease the expression of pERK and pAKT, and thus apoptosis of blood cancer cells is increased, thereby exhibiting an effect of preventing or treating blood cancers. In addition, by administering the composition according to one aspect together with an existing anticancer agent, a synergistic effect showing more significant apoptosis than when an existing anticancer agent was administered was confirmed, which can contribute to the blood cancer treatment market/industry.

公开(公告)号：US12194043B2

公开(公告)日：2025-01-14

申请号：US17369203

申请日：2021-07-07

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Philip Liaw ,  Brian D. Frenzel

IPC: A61K31/519 ,  A61K31/7072 ,  A61P11/00

Abstract: The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof.

公开(公告)号：US12171744B2

公开(公告)日：2024-12-24

申请号：US17337952

申请日：2021-06-03

Applicant: Presage Biosciences, Inc.

Inventor： Richard Klinghoffer ,  Joyoti Dey

IPC: A61K31/4025 ,  A61K9/00 ,  A61K31/407 ,  A61K31/453 ,  A61K31/519 ,  A61K31/635 ,  A61K31/69 ,  A61K31/7072 ,  A61K45/06 ,  A61K47/06 ,  A61P35/02

Abstract: The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula (I): or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.

公开(公告)号：US20240376143A1

公开(公告)日：2024-11-14

申请号：US18560583

申请日：2022-05-17

Applicant: The Johns Hopkins University

Inventor： Marc M. GREENBERG ,  Shelby C. YUHAS

IPC: C07H19/10 ,  A61K31/7072 ,  A61P35/00 ,  C12N9/99 ,  G01N21/64 ,  G01N33/68

Abstract: Methods and compounds are disclosed for irreversibly inhibiting a DNA polymerase, including DNA polymerase β (pol β). Also disclosed are methods for inducing a synthetic lethality in a breast cancer type 1 (BRCA1)-deficient cancer cell, the method comprising inhibiting DNA polymerase β by administering a presently disclosed pol β inhibitor.

公开(公告)号：US20240358735A1

公开(公告)日：2024-10-31

申请号：US18681728

申请日：2022-08-26

Applicant: BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. ,  CORNELL UNIVERSITY

Inventor： Frank C. SCHROEDER ,  Chester J. J. WROBEL ,  Brian J. CURTIS ,  Jingfang YU ,  Pedro RODRIGUES ,  Arnaud TAUFFENBERGER ,  Bingsen ZHANG ,  Aleksandra SKIRYCZ ,  Venkatesh Periyakavanam THIRUMALAIKUMAR

IPC: A61K31/7076 ,  A61K31/7028 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  A61K47/26 ,  C07H15/22 ,  C07H17/02

CPC classification number: A61K31/7076 ,  A61K31/7028 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  A61K47/26 ,  C07H15/22 ,  C07H17/02

Abstract: The invention relates to modular glucosides (MOGLs), therapeutic compositions containing such MOGLs and methods of using the same.

公开(公告)号：US20240309039A1

公开(公告)日：2024-09-19

申请号：US18632908

申请日：2024-04-11

Applicant: EMORY UNIVERSITY

Inventor： Abel de la Rosa ,  Gregory R. Bluemling

IPC: C07H19/10 ,  A61K9/127 ,  A61K31/7072 ,  A61K45/06 ,  A61P31/20 ,  C07B59/00 ,  C07D405/04 ,  C07H19/09

CPC classification number: C07H19/10 ,  A61K9/127 ,  A61K31/7072 ,  A61K45/06 ,  A61P31/20 ,  C07B59/005 ,  C07D405/04 ,  C07H19/09

Abstract: Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.

公开(公告)号：US20240226129A1

公开(公告)日：2024-07-11

申请号：US18528550

申请日：2023-12-04

Applicant: Shuttle Pharmaceuticals, Inc.

Inventor： Scott Grindrod ,  Mira Jung ,  Olga Timofeeva ,  Milton Brown ,  Anatoly Dritschilo

IPC: A61K31/7072 ,  A61K31/513 ,  A61K33/243

CPC classification number: A61K31/7072 ,  A61K31/513 ,  A61K33/243 ,  A61K2121/00

Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.

公开(公告)号：US20240197767A1

公开(公告)日：2024-06-20

申请号：US17768669

申请日：2020-10-09

Applicant: Helperby Therapeutics Limited

Inventor： Professor Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61K31/65 ,  A61P31/04

CPC classification number: A61K31/7072 ,  A61K31/65 ,  A61P31/04

Abstract: The present invention relates to a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a tetracycline antibiotic or a pharmaceutically acceptable derivative or prodrug thereof, for use in treating a microbial infection, particularly a bacterial infection such as a urinary tract infection.

公开(公告)号：US20240175863A1

公开(公告)日：2024-05-30

申请号：US18278995

申请日：2022-03-03

Applicant: The Regents of University of Californa

Inventor： Arjun Deb

IPC: G01N33/50 ,  A61K31/352 ,  A61K31/7072 ,  A61K45/06 ,  A61P9/10

CPC classification number: G01N33/5061 ,  A61K31/352 ,  A61K31/7072 ,  A61K45/06 ,  A61P9/10 ,  G01N33/502 ,  G01N2333/916 ,  G01N2800/325

Abstract: Provided herein are methods and compositions related to monitoring ENPP1 activity and the treatment of cardiac injury using pyrimidine nucleotides.